{"id":457416,"date":"2021-03-15T08:03:19","date_gmt":"2021-03-15T12:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457416"},"modified":"2021-03-15T08:03:19","modified_gmt":"2021-03-15T12:03:19","slug":"aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/","title":{"rendered":"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">\n        <em>Second Largest Medicaid <\/em><br \/>\n        <em>population in the U.S.<\/em><br \/>\n        \n      <\/p>\n<p>AUSTIN, Texas, March  15, 2021  (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health Inc. (Nasdaq: AWH), today announced its wholly owned subsidiary, Aspira Labs, is now credentialed with New York State\u2019s Medicaid program for an estimated additional 6.5 million Medicaid lives. NY State Medicaid will begin to cover Aspira\u2019s OVA1\u00ae test effective April 1, 2021.<\/p>\n<p>New York has the second largest state Medicaid population in the U.S. and Aspira Labs is now credentialed in the top 9 states by Medicaid population size, including California, Florida, Illinois, Pennsylvania, Texas, and now New York. The addition of New York brings Aspira Labs\u2019 total credentialed Medicaid population to almost 60 M Medicaid lives, which is over 78% of the U.S. Medicaid population. Aspira Labs is the only U.S. provider for Aspira\u2019s proprietary OVA1\u00ae test, an FDA-cleared, ACOG recommended, and CMS supported ovarian cancer risk assessment for women with a pelvic mass.<\/p>\n<p>The addition of 6.5M NY State Medicaid lives will also increase the total coverage for OVA1\u00ae testing to 179M nationwide. Positive coverage for OVA1\u00ae, combined with credentialing for Aspira Labs, opens up opportunities for follow-on commercial Medicaid contracts in NY State, especially when combined with peer-reviewed published evidence documenting OVA1\u00ae\u2019s early detection and negative predictive value performance over CA125, and its marked performance in Black women as compared to CA125.<\/p>\n<p>\u201cAdding New York Medicaid coverage provides a large population of patients access to OVA1\u00ae and continues our mission to remove barriers for ALL women,\u201d said Valerie Palmieri, President and CEO of Aspira Women\u2019s Health, Inc. \u201cAdding additional Medicaid states is a key cornerstone to our resolution of the health disparities in Ovarian Cancer risk detection. We are pleased to announce Aspira\u2019s enrollment as a participating provider with State of New York Medicaid.\u201d<\/p>\n<p>\n        <strong>About Aspira Women\u2019s Health Inc.<\/strong><br \/>\n        <br \/>Aspira Women\u2019s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women\u2019s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women\u2019s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1\u00ae plus includes our FDA-cleared products, OVA1\u00ae and OVERA\u00ae, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX<sup>TM<\/sup> testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women\u2019s Health is delivering a portfolio of pelvic mass products over a patient\u2019s lifetime with our cutting-edge research. The next generation of products in development are OVASight<sup>TM<\/sup> and EndoCheck<sup>TM<\/sup>. Visit our website for more information at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3-UnjqZ7-BsXEPK4xmFvyyl_Babccn89HCmsaMh6XbWkKJ-xuxpcYGe5yUJ_OJu9g6YegfHJVthEOqO9jEKsIw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.aspirawh.com<\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Ashley R. Robinson <br \/>LifeSci Advisors, LLC <br \/>Tel 617-430-7577<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=drRz5AZUEY9o3Q8MCa8J5qjOQlykPTZoHHfgQq8V5-j0_ZDcJp7Tl3iBRuAWRCUNisQGxOD-juwS2CztRBWc4mBrIa6FQhBiyRi7LvCi2Mw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Arr@lifesciadvisors.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e562eb71-5f91-43d4-a0f5-399698b82111\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Second Largest Medicaid population in the U.S. AUSTIN, Texas, March 15, 2021 (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health Inc. (Nasdaq: AWH), today announced its wholly owned subsidiary, Aspira Labs, is now credentialed with New York State\u2019s Medicaid program for an estimated additional 6.5 million Medicaid lives. NY State Medicaid will begin to cover Aspira\u2019s OVA1\u00ae test effective April 1, 2021. New York has the second largest state Medicaid population in the U.S. and Aspira Labs is now credentialed in the top 9 states by Medicaid population size, including California, Florida, Illinois, Pennsylvania, Texas, and now New York. The addition of New York brings Aspira Labs\u2019 total credentialed Medicaid population to almost 60 M Medicaid lives, which is over 78% of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457416","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Second Largest Medicaid population in the U.S. AUSTIN, Texas, March 15, 2021 (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health Inc. (Nasdaq: AWH), today announced its wholly owned subsidiary, Aspira Labs, is now credentialed with New York State\u2019s Medicaid program for an estimated additional 6.5 million Medicaid lives. NY State Medicaid will begin to cover Aspira\u2019s OVA1\u00ae test effective April 1, 2021. New York has the second largest state Medicaid population in the U.S. and Aspira Labs is now credentialed in the top 9 states by Medicaid population size, including California, Florida, Illinois, Pennsylvania, Texas, and now New York. The addition of New York brings Aspira Labs\u2019 total credentialed Medicaid population to almost 60 M Medicaid lives, which is over 78% of &hellip; Continue reading &quot;Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T12:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021\",\"datePublished\":\"2021-03-15T12:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/\"},\"wordCount\":502,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/\",\"name\":\"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw==\",\"datePublished\":\"2021-03-15T12:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/","og_locale":"en_US","og_type":"article","og_title":"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021 - Market Newsdesk","og_description":"Second Largest Medicaid population in the U.S. AUSTIN, Texas, March 15, 2021 (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health Inc. (Nasdaq: AWH), today announced its wholly owned subsidiary, Aspira Labs, is now credentialed with New York State\u2019s Medicaid program for an estimated additional 6.5 million Medicaid lives. NY State Medicaid will begin to cover Aspira\u2019s OVA1\u00ae test effective April 1, 2021. New York has the second largest state Medicaid population in the U.S. and Aspira Labs is now credentialed in the top 9 states by Medicaid population size, including California, Florida, Illinois, Pennsylvania, Texas, and now New York. The addition of New York brings Aspira Labs\u2019 total credentialed Medicaid population to almost 60 M Medicaid lives, which is over 78% of &hellip; Continue reading \"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T12:03:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021","datePublished":"2021-03-15T12:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/"},"wordCount":502,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/","name":"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw==","datePublished":"2021-03-15T12:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczOCM0MDYzMzI5IzUwMDA0NTYzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announcement-new-york-state-medicaid-now-considers-ova1-medically-necessary-as-of-april-1-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aspira Women\u2019s Health Inc. Announcement New York State Medicaid Now Considers OVA1\u00ae Medically Necessary as of April 1, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457416"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457416\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}